Type Private Headquarters Netherlands | Industry Biotechnology Founded 2010 | |
 | ||
Founder Dr. Floris van Delft and Dr. Sander van Berkel | ||
Synaffix enables adcs for oncology that are both safer and more effective
Synaffix is a preclinical-stage biotechnology company headquartered in the Netherlands that is exclusively focused on the development of technology for antibody-drug conjugates (ADCs) that are used in the treatment of cancer. ADCs utilize potent small molecule payloads, similar to those used for chemotherapy, but are intended to target only the cancer cells and spare normal, healthy tissues.
The proprietary technology of Synaffix is adaptable for the treatment of a wide variety of cancer types and is designed to further improve the therapeutic index of these targeted cancer therapeutics, compared to both FDA-approved ADCs. Data indicates that the resulting ADCs are not only safer and better tolerated but also significantly more efficacious than the most advanced targeted-cancer therapeutics available for breast cancer as well as lymphoma, Kadcyla and Adcetris respectively.
Synaffix was founded in 2010 based on inventions made in the field of copper-free click chemistry at the Radboud University in Nijmegen. This chemistry was combined with the use of enzymatic antibody modification in order to facilitate the generation of targeted cancer therapeutics.
In October 2016, Synaffix made the first public disclosure of its commercial license agreement with ADC Therapeutics Sarl (ADCT). Under the terms of the Agreement, ADCT may develop one or multiple products using Synaffix technology.